Acquisition creates leading pan-isotype cancer antibody company
Epsilogen has completed the acquisition of TigaTx, a biotechnology company developing engineered immunoglobulin A (IgA) antibodies. As a result, US-based TigaTx will become a wholly owned subsidiary of Epsilogen. Dr Sonia Gulati, a Principal at Global BioAccess Fund, has joined the Epsilogen Board of Directors. … Read More
